MedTrace Logo

Atherosclerosis Monitoring and Atherogenicity Reduction Study

NCT01734707 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-11-28

No results posted yet for this study

Summary

This study was designed to estimate the effect of two-year treatment with time-released garlic-based drug Allicor on the progression of carotid atherosclerosis in double-blinded placebo-controlled randomized clinical trial.

Conditions

  • Carotid Atherosclerosis

Interventions

DIETARY_SUPPLEMENT

Allicor

DRUG

Placebo

Sugar pill manufactured to mimic Allicor 150 mg tablet

Sponsors & Collaborators

  • Institute for Atherosclerosis Research, Russia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2005-01-31
Completion
2005-10-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01734707 on ClinicalTrials.gov